Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
January 24, 2025 at 06:02 AM EST
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
 |
||||||||||||
|
||||||||||||
| About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map | ||||||||||||
Photos copyright by Jay Graham Photographer
